# Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

> **NCT00346229** · PHASE1 · TERMINATED · sponsor: **Duke University** · enrollment: 29 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** lyso-thermosensitive liposomal doxorubicin(Thermodox)
- **PROCEDURE:** hyperthermia treatment

## Key facts

- **NCT ID:** NCT00346229
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2016-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346229, "Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00346229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*